PFD report

Michael Samuel Ian Anthony · Prevention of Future Deaths report

Pin Get email alerts Request correction

Issued 9 Apr 2014•Inner South London

Report record

Published report and response evidence

This page connects the concerns raised in this report with statements found in recipients’ published responses. A link shows a clear evidence connection; it does not assign responsibility.

View original report
Concerns
2

Raised in this report

Recipients
2

Named on the report

Responses found
1

Of 2 recipients

Stated actions
1

Described in responses

Source document

Full report text

This is the full text from the original published report.

Open published report

Concerns and recipient responses

Select any concern, action or position to view the source wording.

Report evidence summary

Concerns raised2

  1. Failure to establish whether Gabapentin is contraindicated for patients with severe Type 1 diabetes
    Part of recurring concern: Unsafe medication prescribing
  2. Lack of prescriber awareness of Gabapentin's rare side effect of precipitating diabetic coma
    Part of recurring concern: Failure to identify clinically significant medication risksPart of recurring concern: Unreliable clinician management of medication side effects
Responses linked to these concerns

Each statement is shown once, even when linked to more than one concern.

Actions described in response An action is something a recipient says it has done, is doing, or plans to do in response to a concern raised.1

  1. Action

    Build the drug-safety review into day-to-day clinical practice.

    Stated by Guy'S and St Thomas' NHS Foundation TrustStated completedThe respondent said that this action was complete when they made their response on 9 April 2014.

Respondent positions A position is what a recipient says about a concern when it does not describe a specific action.1

  1. Position

    Gabapentin should not be withheld from diabetic patients because it is licensed for painful diabetic neuropathy within specified doses.

    Stated by Guy'S and St Thomas' NHS Foundation TrustDisputes the concernThe respondent disagreed with part of the concern or the basis for it.

Source evidence

How this individual concern was interpreted

PFD Monitor created a concise, searchable interpretation from the report wording shown below. Response links show a clear evidence connection; they do not assign responsibility.

PFD Monitor interpretation

Failure to establish whether Gabapentin is contraindicated for patients with severe Type 1 diabetes

Wider context from the report

“(1) It was not known whether Gabapentin was contraindicated to be prescribed in the deceased, who suffered severe Type 1 diabetes, or whether the prescribing doctors were aware of the rare side effect of Gabapentin in precipitating diabetic coma. If they were not there would be a potentially avoidable risk to other patients. ”

Is this part of a recurring concern?

Yes — Unsafe medication prescribing.

Open source report

Source evidence

How this individual concern was interpreted

PFD Monitor created a concise, searchable interpretation from the report wording shown below. Response links show a clear evidence connection; they do not assign responsibility.

PFD Monitor interpretation

Lack of prescriber awareness of Gabapentin's rare side effect of precipitating diabetic coma

Wider context from the report

“(1) It was not known whether Gabapentin was contraindicated to be prescribed in the deceased, who suffered severe Type 1 diabetes, or whether the prescribing doctors were aware of the rare side effect of Gabapentin in precipitating diabetic coma. If they were not there would be a potentially avoidable risk to other patients. ”

Is this part of a recurring concern?

Yes — Failure to identify clinically significant medication risks; Unreliable clinician management of medication side effects.

Open source report

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Build the drug-safety review into day-to-day clinical practice.

Verbatim wording from the response

“Many thanks for your letter of 10th April last sent to both myself and ████████████████████████ in relation to the above deceased. We note and acknowledge receipt of the Regulation 28 report to prevent future deaths on the above addressed to myself and ████████████████████████. I have asked for full disclosure by email to the coroner’s office of the toxicologist report. In the meantime, we have asked for a review from the regional drug information service at Guy's. This is attached below and forms part of our reflection, learning and response.”

Source location

2014-0161-Response-by-Guys-St-Thomas-NHS-Trust
Page 1 · response
Published 9 April 2014

Open published response

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Gabapentin should not be withheld from diabetic patients because it is licensed for painful diabetic neuropathy within specified doses.

Verbatim wording from the response

“2. We disagree with the statement that gabapentin should not be used in diabetics as it is a licensed medicine in patients with diabetes to controlled symptoms of painful neuropathy. Licensed doses for this indication can go up to 3600 mg/day.[1,2]”

Source location

2014-0161-Response-by-Guys-St-Thomas-NHS-Trust
Page 3 · response
Published 9 April 2014

Open published response

Other statements in published responses

These actions and other statements could not be clearly connected to one concern in this report.

Recipient positions A position is what a recipient says about a concern when they do not describe a specific action.1

  1. 1

    Diabetic ketoacidosis is not recognised as an adverse effect of gabapentin at therapeutic or toxic doses.

    Stated by Guy'S and St Thomas' NHS Foundation TrustDisputes the concernThe respondent disagreed with part of the concern or the basis for it.

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Diabetic ketoacidosis is not recognised as an adverse effect of gabapentin at therapeutic or toxic doses.

Verbatim wording from the response

“1. Diabetic ketoacidosis is not a recognised adverse effect of gabapentin at both therapeutic and toxic doses.[1,2,6]”

Source location

2014-0161-Response-by-Guys-St-Thomas-NHS-Trust
Page 3 · response
Published 9 April 2014

Open published response
Back to top

Information checked against the published report and official responses · Data reviewed 7 Sep 2026 · About data quality and limitations

Official responses located
1/2

Data last updated 7 September 2026